Interferon gamma induced production of indoleamine 2,3 dioxygenase in cultured human synovial cells. 1994

D G Malone, and P W Dolan, and R R Brown, and M V Kalayoglu, and R A Arend, and G I Byrne, and Y Ozaki
Department of Medicine, University of Wisconsin, Madison.

OBJECTIVE Synovial membrane cells from inflamed joints share morphological and functional properties with malignant mesenchymal cells. Interferon gamma (IFN-gamma) has antitumor cell activity related to stimulation of 2,3 indoleamine dioxygenase (IDO), a widely distributed tryptophan catabolizing enzyme. Our objective was to measure synoviocyte IDO production to determine if the varied clinical and in vitro effects of IFN-gamma on nonmalignant immunocompetent cells might involve a similar mechanism. METHODS Using an established radioenzymatic assay, we measured IDO activity in suspensions of freshly isolated cells obtained by enzymatic dispersion of human synovial membrane, and in fresh and longterm (> or = 2 months) cultures of these cells in response to varying concentrations of recombinant human interferons alpha 2a, beta ser, or gamma. RESULTS In fresh and in > or = 2 month-old cultures, IFN-gamma strongly stimulated IDO activity, a corresponding fall in supernatant tryptophan levels, and an elevation in the supernatant concentration of kynurenine, tryptophan's principal metabolite, mRNA for IDO was likewise markedly increased in cells after 4 days' incubation with IFN-gamma. Staining studies indicated that the IDO producing cells in synovium were not typical macrophages. Interferon beta ser had weak IDO stimulatory activity that was in a few cases additive to that of IFN-gamma. In no case did interferon beta ser abrogate IFN-gamma induced IDO activity increases. Interferon alpha 2a also had weak stimulatory activity. CONCLUSIONS IFN-gamma stimulates IDO production and tryptophan metabolism in cultured human synovial cells, and therefore may contribute to this cytokine's in vitro and clinical effects in arthritis and inflammation.

UI MeSH Term Description Entries
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D007477 Ions An atom or group of atoms that have a positive or negative electric charge due to a gain (negative charge) or loss (positive charge) of one or more electrons. Atoms with a positive charge are known as CATIONS; those with a negative charge are ANIONS.
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068556 Interferon beta-1a An interferon beta-1 subtype that has a methionine at position 1, a cysteine at position 17, and is glycosylated at position 80. It functions as an ANTI-VIRAL AGENT and IMMUNOMODULATOR and is used to manage the symptoms of RELAPSING-REMITTING MULTIPLE SCLEROSIS. Avonex,Avonex Pen,Interferon beta 1a,Rebif,beta 1a, Interferon,beta-1a, Interferon
D000068576 Interferon beta-1b A non-glycosylated form of interferon beta-1 that has a serine at position 17. It is used in the treatment of both RELAPSING-REMITTING MULTIPLE SCLEROSIS and CHRONIC PROGRESSIVE MULTIPLE SCLEROSIS. Beta-IFN-1b,Beta-Seron,Betaferon,Betaseron,Extavia,IFN-Beta Ser,Interferon Beta, Ser(17),Interferon Beta, Serine(17),Interferon beta 1b,Ser(17) IFN-beta,Serine(17) Interferon Beta,Beta Seron
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D013194 Staining and Labeling The marking of biological material with a dye or other reagent for the purpose of identifying and quantitating components of tissues, cells or their extracts. Histological Labeling,Staining,Histological Labelings,Labeling and Staining,Labeling, Histological,Labelings, Histological,Stainings

Related Publications

D G Malone, and P W Dolan, and R R Brown, and M V Kalayoglu, and R A Arend, and G I Byrne, and Y Ozaki
June 1986, Journal of interferon research,
D G Malone, and P W Dolan, and R R Brown, and M V Kalayoglu, and R A Arend, and G I Byrne, and Y Ozaki
March 2006, Biology of reproduction,
D G Malone, and P W Dolan, and R R Brown, and M V Kalayoglu, and R A Arend, and G I Byrne, and Y Ozaki
January 2007, Diabetes,
D G Malone, and P W Dolan, and R R Brown, and M V Kalayoglu, and R A Arend, and G I Byrne, and Y Ozaki
January 1989, Journal of leukocyte biology,
D G Malone, and P W Dolan, and R R Brown, and M V Kalayoglu, and R A Arend, and G I Byrne, and Y Ozaki
November 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology,
D G Malone, and P W Dolan, and R R Brown, and M V Kalayoglu, and R A Arend, and G I Byrne, and Y Ozaki
September 1992, Cancer letters,
D G Malone, and P W Dolan, and R R Brown, and M V Kalayoglu, and R A Arend, and G I Byrne, and Y Ozaki
April 2000, Molecular human reproduction,
D G Malone, and P W Dolan, and R R Brown, and M V Kalayoglu, and R A Arend, and G I Byrne, and Y Ozaki
August 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology,
D G Malone, and P W Dolan, and R R Brown, and M V Kalayoglu, and R A Arend, and G I Byrne, and Y Ozaki
October 2013, Life sciences,
D G Malone, and P W Dolan, and R R Brown, and M V Kalayoglu, and R A Arend, and G I Byrne, and Y Ozaki
February 1988, The Journal of biological chemistry,
Copied contents to your clipboard!